The Effect of Insulin Resistance on Reproductive Endocrine and Metabolism of Polycystic Ovary Syndrome

doi:10.12280/gjfckx.20230032

Abstract

Abstract:

Polycystic ovary syndrome (PCOS) represents the most common disease with endocrine dysfunctional in women of reproductive age with multiple reproductive and metabolic phenotypes. About 50%-70% of the PCOS patients have combined insulin resistance (IR). IR plays a significant role in the occurrence and development of PCOS. Not only does IR affect the reproductive endocrine function of PCOS patients, but also increases the risk of metabolic disorders in PCOS patients. IR and hyperandrogenism interact with each other to promote the development of PCOS. IR is associated with the degree of menstrual disorder. IR in partial endometrium of PCOS patients decreases endometrial receptivity. IR aggravates PCOS patients′ disorder of lipid metabolism，promoting the occurrence and development of non-alcoholic fatty liver disease. IR affects the development and function of adipose tissue. Obesity also affects insulin sensitivity. IR can reduce bone formation, hinder bone resorption, and aggravate the risk of osteoporosis, and adversely affects bone metabolism in patients with PCOS. This article elaborating from the above aspects, is expected to provide reference for improving the metabolic disorder and reproductive function of PCOS patients with IR.

Key words: Polycystic ovary syndrome, Insulin resistance, Androgens, Menstrual cycle, Endometrium, Lipid metabolism disorders, Bone and bones

LIU Yin, LU Di, SONG Dian-rong. The Effect of Insulin Resistance on Reproductive Endocrine and Metabolism of Polycystic Ovary Syndrome[J]. Journal of International Obstetrics and Gynecology, 2023, 50(2): 190-195.

References 44

[1]	Joham AE, Norman RJ, Stener-Victorin E, et al. Polycystic ovary syndrome[J]. Lancet Diabetes Endocrinol, 2022, 10(9):668-680. doi: 10.1016/S2213-8587(22)00163-2. doi: 10.1016/S2213-8587(22)00163-2
[2]	乔杰, 李蓉, 李莉, 等. 多囊卵巢综合征——多囊卵巢综合征流行病学研究[J]. 中国实用妇科与产科杂志, 2013, 29(11):849-852.
[3]	Pani A, Gironi I, Di Vieste G, et al. From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management[J]. Int J Endocrinol, 2020, 2020:6276187. doi: 10.1155/2020/6276187. doi: 10.1155/2020/6276187
[4]	Pérez-López FR, Ornat L, López-Baena MT, et al. Circulating kisspeptin and anti-müllerian hormone levels, and insulin resistance in women with polycystic ovary syndrome: A systematic review, meta-analysis, and meta-regression[J]. Eur J Obstet Gynecol Reprod Biol, 2021, 260:85-98. doi: 10.1016/j.ejogrb.2021.03.007. doi: 10.1016/j.ejogrb.2021.03.007 pmid: 33744505
[5]	Cassar S, Misso ML, Hopkins WG, et al. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies[J]. Hum Reprod, 2016, 31(11):2619-2631. doi: 10.1093/humrep/dew243. doi: 10.1093/humrep/dew243
[6]	Maffazioli G, Lopes CP, Heinrich-Oliveira V, et al. Prevalence of metabolic disturbances among women with polycystic ovary syndrome in different regions of Brazil[J]. Int J Gynaecol Obstet, 2020, 151(3):383-391. doi: 10.1002/ijgo.13374. doi: 10.1002/ijgo.13374
[7]	Kim JJ, Hwang KR, Oh SH, et al. Prevalence of insulin resistance in Korean women with polycystic ovary syndrome according to various homeostasis model assessment for insulin resistance cutoff values[J]. Fertil Steril, 2019, 112(5):959-966.e1. doi: 10.1016/j.fertnstert.2019.06.035. doi: S0015-0282(19)30575-8 pmid: 31542165
[8]	Zippl AL, Seeber B, Wildt L. Insulin resistance: still an underestimated factor in polycystic ovary syndrome?[J]. Fertil Steril, 2021, 115(6):1447-1448. doi: 10.1016/j.fertnstert.2021.03.020. doi: 10.1016/j.fertnstert.2021.03.020 pmid: 33863552
[9]	Belenkaia LV, Lazareva LM, Walker W, et al. Criteria, phenotypes and prevalence of polycystic ovary syndrome[J]. Minerva Ginecol, 2019, 71(3):211-223. doi: 10.23736/S0026-4784.19.04404-6. doi: 10.23736/S0026-4784.19.04404-6 pmid: 31089072
[10]	Huang-Doran I, Kinzer AB, Jimenez-Linan M, et al. Ovarian Hyperandrogenism and Response to Gonadotropin-releasing Hormone Analogues in Primary Severe Insulin Resistance[J]. J Clin Endocrinol Metab, 2021, 106(8):2367-2383. doi: 10.1210/clinem/dgab275. doi: 10.1210/clinem/dgab275
[11]	徐芳, 孙淼, 郝松莉, 等. 多囊卵巢综合征不孕症患者胰岛素抵抗和临床特征的相关性分析[J]. 辽宁中医杂志, 2022, 49(7):13-16. doi: 10.13192/j.issn.1000-1719.2022.07.004. doi: 10.13192/j.issn.1000-1719.2022.07.004
[12]	Chien YJ, Chang CY, Wu MY, et al. Effects of Curcumin on Glycemic Control and Lipid Profile in Polycystic Ovary Syndrome: Systematic Review with Meta-Analysis and Trial Sequential Analysis[J]. Nutrients, 2021, 13(2):684. doi: 10.3390/nu13020684. doi: 10.3390/nu13020684
[13]	吴亚妹, 马宁, 黄兹宝, 等. 胰岛素抵抗影响多囊卵巢综合征发病及机制的研究进展[J]. 生殖医学杂志, 2021, 30(9):1247-1251. doi: 10.3969/j.issn.1004-3845.2021.09.023. doi: 10.3969/j.issn.1004-3845.2021.09.023
[14]	陆新虹, 杨海燕, 罗佐杰, 等. 不同胰岛素抵抗状态下多囊卵巢综合征患者内分泌指标与卵巢超声特征的相关性研究[J]. 中国糖尿病杂志, 2015, 23(1):40-42. doi: 10.3969/j.issn.1006-6187.2015.01.011. doi: 10.3969/j.issn.1006-6187.2015.01.011
[15]	Li X, Yang D, Pan P, et al. The Degree of Menstrual Disturbance Is Associated With the Severity of Insulin Resistance in PCOS[J]. Front Endocrinol(Lausanne), 2022, 13:873726. doi: 10.3389/fendo.2022.873726. doi: 10.3389/fendo.2022.873726
[16]	Kicińska AM, Stachowska A, Kajdy A, et al. Successful Implementation of Menstrual Cycle Biomarkers in the Treatment of Infertility in Polycystic Ovary Syndrome-Case Report[J]. Healthcare(Basel), 2023, 11(4):616. doi: 10.3390/healthcare11040616. doi: 10.3390/healthcare11040616
[17]	Niu J, Lu M, Liu B. Association between insulin resistance and abnormal menstrual cycle in Chinese patients with polycystic ovary syndrome[J]. J Ovarian Res, 2023, 16(1):45. doi: 10.1186/s13048-023-01122-4. doi: 10.1186/s13048-023-01122-4
[18]	Brower M, Brennan K, Pall M, et al. The severity of menstrual dysfunction as a predictor of insulin resistance in PCOS[J]. J Clin Endocrinol Metab, 2013, 98(12): E1967-E1971. doi: 10.1210/jc.2013-2815. doi: 10.1210/jc.2013-2815
[19]	童一希. 多囊卵巢综合征患者月经周期异常与糖脂代谢及胰岛功能相关性[J]. 中国计划生育学杂志, 2021, 29(9):1902-1906. doi: 10.3969/j.issn.1004-8189.2021.09.028. doi: 10.3969/j.issn.1004-8189.2021.09.028
[20]	Ezeh U, Pisarska MD, Azziz R. Association of severity of menstrual dysfunction with hyperinsulinemia and dysglycemia in polycystic ovary syndrome[J]. Hum Reprod, 2022, 37(3):553-564. doi: 10.1093/humrep/deac001. doi: 10.1093/humrep/deac001
[21]	尹丽红, 焦琳, 陈裕, 等. 多囊卵巢综合征大鼠子宫内膜中PI3K/AKT通路相关蛋白表达异常与胰岛素抵抗的关系[J]. 中国实验动物学报, 2022, 30(6):777-783. doi: 10.3969/j.issn.1005-4847.2022.06.006. doi: 10.3969/j.issn.1005-4847.2022.06.006
[22]	金婕, 熊文倩, 刘义. 上皮-间质转化和蜕膜化与子宫内膜容受性[J]. 国际妇产科学杂志, 2022, 49(3):325-329. doi: 10.12280/gjfckx.20210881. doi: 10.12280/gjfckx.20210881
[23]	Zhang C, Yang C, Li N, et al. Elevated insulin levels compromise endometrial decidualization in mice with decrease in uterine apoptosis in early-stage pregnancy[J]. Arch Toxicol, 2019, 93(12):3601-3615. doi: 10.1007/s00204-019-02601-8. doi: 10.1007/s00204-019-02601-8 pmid: 31642978
[24]	Sumarac-Dumanovic M, Apostolovic M, Janjetovic K, et al. Downregulation of autophagy gene expression in endometria from women with polycystic ovary syndrome[J]. Mol Cell Endocrinol, 2017, 440:116-124. doi: 10.1016/j.mce.2016.11.009. doi: S0303-7207(16)30469-5 pmid: 27845161
[25]	Bai X, Zheng L, Li D, et al. Research progress of endometrial receptivity in patients with polycystic ovary syndrome: a systematic review[J]. Reprod Biol Endocrinol, 2021, 19(1):122. doi: 10.1186/s12958-021-00802-4. doi: 10.1186/s12958-021-00802-4
[26]	Chang EM, Han JE, Seok HH, et al. Insulin resistance does not affect early embryo development but lowers implantation rate in in vitro maturation-in vitro fertilization-embryo transfer cycle[J]. Clin Endocrinol(Oxf), 2013, 79(1):93-99. doi: 10.1111/cen.12099. doi: 10.1111/cen.12099
[27]	Guo F, Gong Z, Fernando T, et al. The Lipid Profiles in Different Characteristics of Women with PCOS and the Interaction Between Dyslipidemia and Metabolic Disorder States: A Retrospective Study in Chinese Population[J]. Front Endocrinol(Lausanne), 2022, 13:892125. doi: 10.3389/fendo.2022.892125. doi: 10.3389/fendo.2022.892125
[28]	赵红莉, 韦洪江, 贾晓江, 等. 多囊卵巢综合征伴与不伴胰岛素抵抗患者糖脂代谢情况比较[J]. 中国妇幼保健, 2020, 35(12):2183-2185. doi: 10.19829/j.zgfybj.issn.1001-4411.2020.12.012. doi: 10.19829/j.zgfybj.issn.1001-4411.2020.12.012
[29]	Sakurai Y, Kubota N, Yamauchi T, et al. Role of Insulin Resistance in MAFLD[J]. Int J Mol Sci, 2021, 22(8):4156. doi: 10.3390/ijms22084156. doi: 10.3390/ijms22084156
[30]	Manzano-Nunez R, Santana-Dominguez M, Rivera-Esteban J, et al. Non-Alcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome: A Systematic Review, Meta-Analysis, and Meta-Regression[J]. J Clin Med, 2023, 12(3):856. doi: 10.3390/jcm12030856. doi: 10.3390/jcm12030856
[31]	Harsha Varma S, Tirupati S, Pradeep T, et al. Insulin resistance and hyperandrogenemia independently predict nonalcoholic fatty liver disease in women with polycystic ovary syndrome[J]. Diabetes Metab Syndr, 2019, 13(2):1065-1069. doi: 10.1016/j.dsx.2018.12.020. doi: S1871-4021(18)30595-2 pmid: 31336445
[32]	Macut D, Tziomalos K, Božić-Antić I, et al. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome[J]. Hum Reprod, 2016, 31(6):1347-1353. doi: 10.1093/humrep/dew076. doi: 10.1093/humrep/dew076
[33]	Giannouli A, Efthymiou V, Konidari M, et al. The Burden of Non-Alcoholic Fatty Liver Disease in Adolescents with Polycystic Ovary Syndrome: A Case-Control Study[J]. J Clin Med, 2023, 12(2):557. doi: 10.3390/jcm12020557. doi: 10.3390/jcm12020557
[34]	Shengir M, Chen T, Guadagno E, et al. Non-alcoholic fatty liver disease in premenopausal women with polycystic ovary syndrome: A systematic review and meta-analysis[J]. JGH Open, 2021, 5(4):434-445. doi: 10.1002/jgh3.12512. doi: 10.1002/jgh3.12512 pmid: 33860093
[35]	袁莹莹, 赵君利. 多囊卵巢综合征流行病学特点[J]. 中国实用妇科与产科杂志, 2019, 35(3):261-264. doi: 10.19538/j.fk2019030102. doi: 10.19538/j.fk2019030102
[36]	Ezeh U, Chen IY, Chen YH, et al. Adipocyte Insulin Resistance in PCOS: Relationship With GLUT-4 Expression and Whole-Body Glucose Disposal and β-Cell Function[J]. J Clin Endocrinol Metab, 2020, 105(7):e2408-e2420. doi: 10.1210/clinem/dgaa235. doi: 10.1210/clinem/dgaa235
[37]	Cardoso NS, Ribeiro VB, Dutra S, et al. Polycystic ovary syndrome associated with increased adiposity interferes with serum levels of TNF-alpha and IL-6 differently from leptin and adiponectin[J]. Arch Endocrinol Metab, 2020, 64(1):4-10. doi: 10.20945/2359-3997000000197. doi: S2359-39972020000100004 pmid: 32187268
[38]	Behboudi-Gandevani S, Ramezani Tehrani F, Rostami Dovom M, et al. Insulin resistance in obesity and polycystic ovary syndrome: systematic review and meta-analysis of observational studies[J]. Gynecol Endocrinol, 2016, 32(5):343-353. doi: 10.3109/09513590.2015.1117069. doi: 10.3109/09513590.2015.1117069 pmid: 27052492
[39]	Oguz SH, İdilman I, Helvaci N, et al. Tissue fat quantification by magnetic resonance imaging: proton density fat fraction in polycystic ovary syndrome[J]. Reprod Biomed Online, 2020, 41(2):329-334. doi: 10.1016/j.rbmo.2020.04.024. doi: S1472-6483(20)30266-2 pmid: 32576491
[40]	Pereira-Eshraghi CF, Chiuzan C, Zhang Y, et al. Obesity and Insulin Resistance, Not Polycystic Ovary Syndrome, Are Independent Predictors of Bone Mineral Density in Adolescents and Young Women[J]. Horm Res Paediatr, 2019, 92(6):365-371. doi: 10.1159/000507079. doi: 10.1159/000507079
[41]	Salari-Moghaddam A, Sadeghi O, Keshteli AH, et al. Metformin use and risk of fracture: a systematic review and meta-analysis of observational studies[J]. Osteoporos Int, 2019, 30(6):1167-1173. doi: 10.1007/s00198-019-04948-1. doi: 10.1007/s00198-019-04948-1 pmid: 30927035
[42]	Piovezan JM, Premaor MO, Comim FV. Negative impact of polycystic ovary syndrome on bone health: a systematic review and meta-analysis[J]. Hum Reprod Update, 2019, 25(5):633-645. doi: 10.1093/humupd/dmz020. doi: 10.1093/humupd/dmz020 pmid: 31374576
[43]	Karadağ C, Yoldemir T, Gogas Yavuz D. Determinants of low bone mineral density in premenopausal polycystic ovary syndrome patients[J]. Gynecol Endocrinol, 2017, 33(3):234-237. doi: 10.1080/09513590.2016.1250256. doi: 10.1080/09513590.2016.1250256 pmid: 27908213
[44]	Aldhafiri FK, Abdelgawad FE, Mohamed Bakri GM, et al. Insulin Resistance and Bone Metabolism Markers in Women with Polycystic Ovary Syndrome: A Cross-Sectional Study on Females from the Islamic University Medical Center[J]. Medicina(Kaunas), 2023, 59(3):593. doi: 10.3390/medicina59030593. doi: 10.3390/medicina59030593